{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:59Z","timestamp":1792093799592,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/01364"],"award-info":[{"award-number":["FIS PI22\/01364"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP15\/00027"],"award-info":[{"award-number":["PMP15\/00027"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00021"],"award-info":[{"award-number":["PMP22\/00021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102924","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T02:48:23Z","timestamp":1701398903000},"page":"102924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-5070","authenticated-orcid":false,"given":"Montserrat","family":"Marques-Pamies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3709-1850","authenticated-orcid":false,"given":"Mireia","family":"Jord\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102924_bib0001","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0003","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0006","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The Future of Somatostatin Receptor Ligands in Acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/jcm12010025","article-title":"Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study","volume":"12","author":"Berton","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.arcmed.2023.102924_bib0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2265.1988.tb02890.x","article-title":"Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical \u2018cure\u2019","volume":"29","author":"Lamberts","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11102-005-1756-2","article-title":"Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve \u2018safe\u2019 growth hormone levels","volume":"7","author":"Lindsay","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2004.02191.x","article-title":"The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0011","first-page":"227","article-title":"Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR","volume":"62","author":"Jenkins","year":"2004","journal-title":"Horm Res"},{"key":"10.1016\/j.arcmed.2023.102924_bib0012","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2008-1065339","article-title":"A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.arcmed.2023.102924_bib0013","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2265.2011.03982.x","article-title":"Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure","volume":"74","author":"Carlsen","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0014","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ghir.2005.02.007","article-title":"Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly","volume":"15","author":"Biermasz","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.arcmed.2023.102924_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0022-3859.62421","article-title":"The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly","volume":"56","author":"Bandgar","year":"2010","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.arcmed.2023.102924_bib0016","doi-asserted-by":"crossref","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.arcmed.2023.102924_bib0017","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1590\/S0004-27302005000300010","article-title":"Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR","volume":"49","author":"Taboada","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1590\/S0004-27302004000200007","article-title":"Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly","volume":"48","author":"Halah","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0019","first-page":"700","article-title":"Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests","volume":"85","author":"Schmidt","year":"1990","journal-title":"Med Klin Munich"},{"key":"10.1016\/j.arcmed.2023.102924_bib0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2265.2005.02278.x","article-title":"The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly","volume":"62","author":"Gilbert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0021","first-page":"2356","article-title":"Prediction of efficacy of octreotide therapy in patients with acromegaly","volume":"81","author":"Colao","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly","volume":"153","author":"de Herder","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0023","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/eje.1.02073","article-title":"The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly","volume":"154","author":"Pokrajac","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0024","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.90.P411","article-title":"Usefulness of the short version of the acute octreotide test for prediction of first-generation somatostatin receptor ligands response in acromegaly: a validation study with the ACROFAST cohort","author":"Marques-Pamies","year":"2023","journal-title":"Bioscientifica (Endocrine Abstracts)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0025","first-page":"1416","article-title":"Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy","volume":"79","author":"Pl\u00f6ckinger","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0026","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF03347995","article-title":"111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients","volume":"20","author":"Legovini","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102924_bib0027","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2265.1997.3361119.x","article-title":"Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide","volume":"47","author":"Borson-Chazot","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF01390518","article-title":"Somatostatin receptor scintigraphy in patients with pituitary adenoma","volume":"20","author":"Rieger","year":"1997","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.arcmed.2023.102924_bib0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF03343538","article-title":"The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas","volume":"22","author":"Colao","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102924_bib0030","first-page":"117","article-title":"Prediction of the pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index","volume":"36","author":"G\u00f6rges","year":"1997","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.arcmed.2023.102924_bib0031","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s40618-021-01523-6","article-title":"Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly","volume":"44","author":"Daniel","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102924_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2022.101502","article-title":"Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study","volume":"67","author":"Durmu\u015f","year":"2022","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.arcmed.2023.102924_bib0033","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00234-016-1728-4","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","journal-title":"Neuroradiology"},{"key":"10.1016\/j.arcmed.2023.102924_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101354","article-title":"Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases","volume":"55","author":"Shen","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.arcmed.2023.102924_bib0035","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0036","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1507\/endocrj.53.125","article-title":"Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage","volume":"53","author":"Oshino","year":"2006","journal-title":"Endocr J"},{"key":"10.1016\/j.arcmed.2023.102924_bib0037","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0038","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0039","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102924_bib0040","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2023.102924_bib0041","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"issue":"Suppl 3","key":"10.1016\/j.arcmed.2023.102924_bib0042","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.21037\/gs.2019.06.04","article-title":"Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas","volume":"8","author":"Tortora","year":"2019","journal-title":"Gland Surg"},{"key":"10.1016\/j.arcmed.2023.102924_bib0043","first-page":"425","article-title":"The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI","volume":"94","author":"Sc\u00e2nteie","year":"2021","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.arcmed.2023.102924_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0045","first-page":"835","article-title":"Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Acromegaly Patients","volume":"29","author":"Durmaz","year":"2019","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.arcmed.2023.102924_bib0046","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0047","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.arcmed.2023.102924_bib0048","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0049","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11102-019-01023-0","article-title":"MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands","volume":"23","author":"Galm","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0050","doi-asserted-by":"crossref","first-page":"e4382","DOI":"10.1210\/clinem\/dgac584","article-title":"Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence?","volume":"107","author":"Gatto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0051","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0052","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0053","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102924_bib0054","first-page":"1","article-title":"Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2023.102924_bib0056","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0057","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in Vitro and in vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0058","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0059","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0060","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.arcmed.2023.102924_bib0061","doi-asserted-by":"crossref","unstructured":"Ilie MD, Tabarin A, Vasiljevic A, et\u00a0al. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study 2022;107:2982\u20132991. Doi 10.1210\/clinem\/dgac512.","DOI":"10.1210\/clinem\/dgac512"},{"key":"10.1016\/j.arcmed.2023.102924_bib0062","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0063","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.arcmed.2023.102924_bib0064","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102924_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102924_bib0066","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0067","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.arcmed.2023.102924_bib0068","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.646210","article-title":"Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly","volume":"12","author":"Gil","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0070","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0071","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/jcem-71-6-1421","article-title":"Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase","volume":"71","author":"Spada","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0072","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0073","first-page":"1604","article-title":"Prognostic and therapeutic consequences of G(s)\u03b1 mutations in somatotroph adenomas","volume":"83","author":"Barlier","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0074","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0075","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0076","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/clinem\/dgac610","article-title":"Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands","volume":"108","author":"Herkenhoff","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0077","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3390\/ijms24032875","article-title":"miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly","volume":"24","author":"Henriques","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2023.102924_bib0078","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40618-018-0988-8","article-title":"GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly","volume":"42","author":"Ferra\u00f9","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102924_bib0079","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.3390\/cancers13194857","article-title":"Gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly","volume":"13","author":"Wildemberg","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.arcmed.2023.102924_bib0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.endonu.2016.03.001","article-title":"The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research","volume":"63","author":"Luque","year":"2016","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.arcmed.2023.102924_bib0081","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/biomedicines10020460","article-title":"Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response","volume":"10","author":"Gil","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.arcmed.2023.102924_bib0082","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35000034","article-title":"The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells","volume":"2","author":"Batlle","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0083","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0084","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102924_bib0085","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2023.102924_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.984877","article-title":"Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain","volume":"13","author":"Biagetti","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0087","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13139-017-0512-7","article-title":"Radiomics as a Quantitative Imaging Biomarker: Practical Considerations and the Current Standpoint in Neuro-oncologic Studies","volume":"52","author":"Park","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"1139","key":"10.1016\/j.arcmed.2023.102924_bib0088","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220401","article-title":"Quality reporting of radiomics analysis in pituitary adenomas: promoting clinical translation","volume":"95","author":"Won","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0089","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11102-020-01077-5","article-title":"Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas","volume":"23","author":"Park","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11102-022-01216-0","article-title":"Machine learning as a clinical decision support tool for patients with acromegaly","volume":"25","author":"Sulu","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102924_bib0091","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.3390\/cells11233846","article-title":"Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly","volume":"11","author":"Rymuza","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.arcmed.2023.102924_bib0092","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresbull.2020.04.018","article-title":"Comprehensive circular RNA profiling reveals that hsa_circ_0001368 is involved in growth hormone-secreting pituitary adenoma development","volume":"161","author":"Du","year":"2020","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.arcmed.2023.102924_bib0093","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/ijms23031413","article-title":"Rno_circ_0001004 Acts as a miR-709 Molecular Sponge to Regulate the Growth Hormone Synthesis and Cell Proliferation","volume":"23","author":"Xiong","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2023.102924_bib0094","doi-asserted-by":"crossref","DOI":"10.1159\/000531200","article-title":"Clinical and proteomic-based molecular characterizations of invasive and noninvasive somatotroph PitNETs","author":"Chen","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102924_bib0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13167-021-00232-7","article-title":"Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches","volume":"12","author":"Li","year":"2021","journal-title":"EPMA J"},{"key":"10.1016\/j.arcmed.2023.102924_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic Classification of Pituitary Neuroendocrine Tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.arcmed.2023.102924_bib0097","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s42003-022-04272-1","article-title":"Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors","volume":"5","author":"Yamato","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784819","article-title":"The Application of Artificial Intelligence and Machine Learning in Pituitary Adenomas","volume":"11","author":"Dai","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2023.102924_bib0099","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13167-021-00246-1","article-title":"Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies","volume":"12","author":"Aydin","year":"2021","journal-title":"EPMA J"},{"key":"10.1016\/j.arcmed.2023.102924_bib0100","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1530\/EC-19-0156","article-title":"A systematic review on machine learning in sellar region diseases: Quality and reporting items","volume":"8","author":"Qiao","year":"2019","journal-title":"Endocr Connect"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:15:13Z","timestamp":1741166113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001625"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102924","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102924"}}